Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients ...

Johnson & Johnson (JNJ) reports a Phase 3 success for its anti-inflammatory drug Tremfya in treating psoriatic arthritis.

Headquartered in New Brunswick, New Jersey, Johnson & Johnson (JNJ) researches and develops, manufactures, and sells various ...

This development comes at a time when pharmaceutical firms are discontinuing discovery efforts in next-generation COVID-19 treatments.

Johnson & Johnson (NYSE:JNJ – Get Free Report)‘s stock had its “neutral” rating reaffirmed by analysts at Guggenheim in a ...

Johnson & Johnson (NYSE:JNJ – Get Free Report)‘s stock had its “outperform” rating reaffirmed by Royal Bank of Canada in a research note issued on Wednesday,Benzinga reports. They currently have a ...

Johnson & Johnson JNJ and Pfizer PFE are two of the world’s largest pharmaceutical companies with diversified healthcare ...

Johnson & Johnson has announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as ...

Johnson & Johnson MedTech (NYSE: JNJ) announced 12-month data from its SmartfIRE clinical trial of the ThermoCool SmartTouch ...

A federal bankruptcy judge has rejected Johnson & Johnson’s latest attempt to settle lawsuits that allege its talc baby ...

Now that the JNJ stock has seen a 7% fall, does the current price point make it attractive? Going by what you pay per dollar ...

RBC Capital analyst Shagun Singh Chadha reiterated a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price ...